{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:34:06Z","timestamp":1790202846006,"version":"4.1.0"},"reference-count":90,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T00:00:00Z","timestamp":1765929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","award":["Seedcorn2024\\100044"],"award-info":[{"award-number":["Seedcorn2024\\100044"]}],"id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000615","name":"Fight for Sight UK","doi-asserted-by":"publisher","award":["RESSGA2510"],"award-info":[{"award-number":["RESSGA2510"]}],"id":[{"id":"10.13039\/501100000615","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000288","name":"Royal Society","doi-asserted-by":"publisher","award":["RG\\R1\\251126"],"award-info":[{"award-number":["RG\\R1\\251126"]}],"id":[{"id":"10.13039\/501100000288","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bpspubs.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology Res &amp; Perspec"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Fluoroquinolones (FQs) are widely prescribed antibiotics; however, increasing concerns have arisen over their potential to cause disabling and irreversible adverse effects. Using real\u2010world data from the FDA Adverse Event Reporting System (FAERS) (2011\u20132024), we performed disproportionality analyses on psychiatric and eye\u2010related adverse events (AEs) using reporting odds ratios (RORs). Of 44\u2009895 FQ\u2010associated adverse event reports, 8518 cases exhibited psychiatric AEs whilst 4367 cases displayed eye\u2010related AEs. Among six FDA\u2010approved FQs, three (ciprofloxacin\/levofloxacin\/moxifloxacin) showed safety signals for psychiatric disorders and four (ciprofloxacin\/levofloxacin\/moxifloxacin\/ofloxacin) for eye\u2010related disorders. Eight psychiatric and nine eye\u2010related AEs were commonly reported across multiple FQs. Importantly, moxifloxacin exhibited unique safety signals for ocular\u2010related toxicity, including iris transillumination defect [ROR: 6604.89 (4736.76\u20139209.81)], iris hypopigmentation [1887.66 (1175.44\u20133031.42)], and pigment dispersion syndrome [2360.62 (1432.71\u20133889.51)], raising concern for\u00a0potential progression to pigmentary glaucoma\u2014findings not prominently featured in current safety warnings. Additionally, systematic characterization of suicide cases revealed striking male predominance despite females comprising the majority of psychiatric AEs, identifying middle\u2010aged males as a high\u2010risk demographic. These findings support the need for enhanced pharmacovigilance, particularly regarding moxifloxacin's ocular toxicity and FQs' suicide vulnerability in specific patient subgroups. When FQ prescription becomes unavoidable, robust safety monitoring should be implemented to detect early neuropsychiatric and ocular complications.<\/jats:p>","DOI":"10.1002\/prp2.70206","type":"journal-article","created":{"date-parts":[[2025,12,18]],"date-time":"2025-12-18T06:34:21Z","timestamp":1766039661000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Fluoroquinolone\u2010Associated Psychiatric and Ocular Adverse Events: A Disproportionality Analysis Using Real\u2010World Data From\n                    <scp>FAERS<\/scp>\n                    (2011\u20132024)"],"prefix":"10.1002","volume":"14","author":[{"given":"Hau\u2010Tak","family":"Chau","sequence":"first","affiliation":[{"name":"Department of Medicine, School of Clinical Medicine The University of Hong Kong  Hong Kong Hong Kong SAR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0245-9096","authenticated-orcid":false,"given":"Ngan Pan Bennett","family":"Au","sequence":"additional","affiliation":[{"name":"Department of Comparative Biomedical Sciences, School of Veterinary Medicine University of Surrey  Guildford UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2004.01.005"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568026033452537"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0025-7125(05)70297-2"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2011.03.006"},{"key":"e_1_2_9_6_1","first-page":"E1","article-title":"Fluoroquinolones: Then and Now","volume":"32","author":"Pallo\u2010Zimmerman L. M.","year":"2010","journal-title":"Compendium: Continuing Education for Veterinarians"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab538"},{"key":"e_1_2_9_8_1","unstructured":"ClinCalc \u201cThe Top 300 of 2022 \u201d(2022)."},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab172"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2021.035"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkab176"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2542-5196(21)00280-1"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.a816"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2022.2147924"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.2165\/11587280-000000000-00000"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.3390\/ph16081105"},{"key":"e_1_2_9_17_1","first-page":"1","article-title":"Fluoroquinolones\u2010Related Psychiatric Adverse Events: A Real\u2010World Retrospective and Pharmacovigilance Database Analysis","volume":"24","author":"Li J.","year":"2024","journal-title":"Expert Opinion on Drug Safety"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1435923"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1437376"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-014-0146-y"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101967"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2019.01.006"},{"key":"e_1_2_9_23_1","unstructured":"Y.Peng Y.Song C.Qin andJ.Lin \u201cfaers: R Interface for FDA Adverse Event Reporting System \u201dR Package Version 120 (2024)."},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102684"},{"key":"e_1_2_9_25_1","first-page":"2014","article-title":"A Package for Survival Analysis in S","volume":"2","author":"Therneau T.","year":"2015","journal-title":"R Package Version"},{"key":"e_1_2_9_26_1","unstructured":"A.Kassambara M.Kosinski P.Biecek andS.Fabian \u201csurvminer: Drawing Survival Curves Using \u2018ggplot2\u2019 \u201dR Package Version 2024; 0.5.0."},{"key":"e_1_2_9_27_1","volume-title":"Modern Applied Statistics With S\u2010PLUS","author":"Venables W. N.","year":"2013"},{"key":"e_1_2_9_28_1","unstructured":"D.Robinson A.Hayes andS.Couch \u201cbroom: Convert Statistical Objects Into Tidy Tibbles \u201dR Package Version 2021; 5."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.18637\/jss.v074.i07"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-0-387-98141-3"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.2.4.378"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40121-018-0198-x"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.6205"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.383"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2007.01552.x"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.280500"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku507"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1080\/14740338.2024.2392862"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrs.2006.01.065"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12886\u2010018\u20100939\u20103"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.4103\/nrr.nrr\u2010d\u201025\u201000860"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)70780-7"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2019.0887"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1345811"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuron.2023.11.011"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2019.104492"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00007-10"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.genhosppsych.2007.11.003"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-009-0027-9"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.4103\/2279-042X.192457"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.1177\/0897190016637987"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.2174\/0929867013373435"},{"issue":"3","key":"e_1_2_9_53_1","first-page":"21","article-title":"The Role of GABA in Anxiety Disorders","volume":"64","author":"Lydiard R. B.","year":"2003","journal-title":"Journal of Clinical Psychiatry"},{"key":"e_1_2_9_54_1","first-page":"993","article-title":"Evaluation of the Effects of Ciprofloxcin or Gatifloxacin on Neurotransmitters Levels in Rat Cortex and Hippocampus","volume":"5","author":"Rawi S. M.","year":"2011","journal-title":"African Journal of Pharmacy and Pharmacology"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-00223-4"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf4740"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.12.2207"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.161.1.88"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2018.07.012"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.psym.2011.05.003"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.119.9.1254"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.1997.01100150175004"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-4274(98)00378-6"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1177\/0960327108092295"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-5224.2001.00182.x"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/33.4.685"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.2165\/00002018-200831020-00003"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00917-4"},{"key":"e_1_2_9_69_1","doi-asserted-by":"publisher","DOI":"10.1001\/archophthalmol.2012.2374"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2015.11.008"},{"key":"e_1_2_9_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2004.01.004"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.6061\/clinics\/2013(07)02"},{"key":"e_1_2_9_73_1","doi-asserted-by":"publisher","DOI":"10.3109\/09273948.2012.670359"},{"key":"e_1_2_9_74_1","doi-asserted-by":"publisher","DOI":"10.1186\/1869-5760-3-10"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-9071.2009.01920.x"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03282-z"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.3109\/02713683.2012.746991"},{"key":"e_1_2_9_78_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2121273119"},{"key":"e_1_2_9_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-022-00233-8"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.860070"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2009.234"},{"key":"e_1_2_9_82_1","first-page":"10","article-title":"Antibacterial Drugs for Community\u2010Acquired Pneumonia","volume":"63","year":"2021","journal-title":"Medical Letter on Drugs and Therapeutics"},{"key":"e_1_2_9_83_1","unstructured":"Department of Health HKS \u201cAustralia: More Prominent Warnings About Serious Side Effects for Fluoroquinolone Antibiotics \u201d(2025)."},{"key":"e_1_2_9_84_1","unstructured":"P.Koomanachai \u201cFluoroquinolones for UTI Treatment in Thailand: A Closer Look at Treatment Strategies \u201dhttps:\/\/www.tga.gov.au\/news\/safety\u2010updates\/more\u2010prominent\u2010warnings\u2010about\u2010serious\u2010side\u2010effects\u2010fluoroquinolone\u2010antibiotics."},{"key":"e_1_2_9_85_1","article-title":"Fluoroquinolone Antibiotics: Prescribe Only as Last Resort, Says UK Regulator","volume":"384","author":"Iacobucci G.","year":"2024","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.29.6.736"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-018-0615-z"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12035-016-0093-y"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1111\/jcpp.12435"},{"key":"e_1_2_9_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41536-022-00243-6"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12911-022-01832-7"}],"container-title":["Pharmacology Research &amp; Perspectives"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70206","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/prp2.70206","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/prp2.70206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:08:40Z","timestamp":1771229320000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/prp2.70206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,17]]},"references-count":90,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1002\/prp2.70206"],"URL":"https:\/\/doi.org\/10.1002\/prp2.70206","archive":["Portico"],"relation":{},"ISSN":["2052-1707","2052-1707"],"issn-type":[{"value":"2052-1707","type":"print"},{"value":"2052-1707","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,17]]},"assertion":[{"value":"2025-06-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70206"}}